Rafferty Asset Management
AMLX icon

Rafferty Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Rafferty Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Buy
+14,758
New +$228K ﹤0.01% 1037
2026
Q1 		– Sell
-17,673
Closed -$213K – 1062
2025
Q4 		$213K Buy
+17,673
New +$240K ﹤0.01% 1089
2024
Q2 		– Sell
-53,201
Closed -$151K – 1170
2024
Q1 		$151K Buy
53,201
+34,881
+190% +$456K ﹤0.01% 1068
2023
Q4 		$270K Buy
18,320
+7,028
+62% +$108K ﹤0.01% 1041
2023
Q3 		$207K Buy
+11,292
New +$239K ﹤0.01% 1052
2023
Q1 		– Sell
-6,298
Closed -$233K – 1142
2022
Q4 		$233K Buy
+6,298
New +$224K ﹤0.01% 1055

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rafferty Asset Management's AMLX Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 14,758 shares worth $265K. The stake represents ﹤0.01% of the portfolio and ranks #1037 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in AMLX as recently as Q4 2025.

Rafferty Asset Management first reported a position in AMLX in Q4 2022 and has held it in 6 quarters since. The position peaked at $270K in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Rafferty Asset Management held 14,758 shares of Amylyx Pharmaceuticals worth $265K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Rafferty Asset Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1037 holding.
  • Rafferty Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
  • Rafferty Asset Management's Amylyx Pharmaceuticals position peaked at $270K in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.